罗氟司特治疗慢性阻塞性肺病的研究进展

Chronic obstructive pulmonary disease (COPD) is a common respiratory disease, mostly seen in people over 40 years old. The main pathological feature of COPD is airflow limitation, one of its characteristics is chronicity, and the disease is prone to recurring attacks, seriously affecting the patient's respiratory system function. Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is caused by the protracted condition of COPD patients affected by various inducements. During this period, patients' various symptoms and airway function impairment are further aggravated, and even respiratory failure occurs. It is a phosphodiesterase-4 (PDE-4) antagonist with strong anti-inflammatory activity. Studies have confirmed its important role in the treatment of AECOPD.

160 patients with chronic obstructive pulmonary disease were selected as the research subjects and randomly divided into an observation group and a control group, with 80 cases in each group. The control group received conventional treatment + doxofylline treatment, and the observation group received oral treatment with roflumilast on the basis of the control group. Both groups were treated for 1 month. After the course of treatment, the total treatment effectiveness of the two groups of patients was compared. The pulmonary function indicators such as VC%, FEV1%, and FVC% and the levels of inflammatory factors such as TNF-α, hs-CRP, and IL-8 were observed in the two groups before and after treatment.

Results: The total effective rate of treatment in the observation group was significantly higher than that in the control group, and the difference was statistically significant (P<0.5); after the course of treatment, the pulmonary function indicators such as VC%, FEV1%, and FVC% in the observation group were significantly higher than those in the control group (P<0.05), and the levels of inflammatory factors such as TNF-α, hs-CRP, and IL-8 were significantly lower than those in the control group (P<0.5).

It is concluded that roflumilast combined with doxofylline is definitely effective in treating chronic obstructive pulmonary disease, and can significantly improve lung function and reduce inflammatory reactions, which deserves clinical attention.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.